Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2008

View Archived Issues

Genentech presents preclinical, clinical data on GDC-0941

Exelixis discloses results on its investigational compounds for cancer

EA-230 lessens kidney damage in porcine peritonitis

SCIO-469 does not meet primary endpoint in a phase II rheumatoid arthritis study

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Anesiva discontinues Zingo, reports results from phase III trial of Adlea

Cell Therapeutics reports results from phase III trial of pixantrone in NHL

Almirall signs agreement with Pfizer to commercialize Astucor in Spain for cardiovascular protection

Sangamo reports results from diabetic neuropathy trial SB-509-601

Lorus completes IND-enabling studies for LOR-253

INNO-406 shows encouraging responses in phase I chronic myeloid leukemia trial

Phase II IMC-1121B study commences in first-line treatment of NSCLC

TNFerade receives FDA fast track designation for pancreatic cancer

Two phase I studies with novel cancer vaccine in two different routes of administration

Marillion and Bracco sign license agreement for cancer drug 177Lu-AMBA

Lipocine completes clinical study establishing feasibility of once-daily ziprasidone

Alba Therapeutics enrolls first European patient in global phase IIb larazotide study

Raptor reports results from phase IIa study of Convivia in ALDH2 deficiency

Novartis reports results from AGELESS study of direct renin inhibitor Rasilez

Acrux adds novel formulations of topical pain relief drugs to product pipeline

Biovitrum extends ReFacto supply agreement with Wyeth

Helion receives funding to continue development of MASP-2

Recent Bayer Schering patent reports novel antiviral agents

Novel NNRTIs reported by Roche

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...